Satellos Bioscience Inc.
MSCL.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 1.51M | 3.21M | 1.60M | 736.00K | 600.00K |
| Gross Profit | -1.51M | -3.21M | -1.60M | -736.00K | -600.00K |
| SG&A Expenses | 8.03M | 7.52M | 6.86M | 6.25M | 6.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.46M | 24.49M | 22.22M | 20.75M | 20.40M |
| Operating Income | -26.46M | -24.49M | -22.22M | -20.75M | -20.40M |
| Income Before Tax | -24.70M | -21.91M | -22.73M | -21.58M | -20.63M |
| Income Tax Expenses | 172.00K | 114.00K | 95.00K | 63.00K | -- |
| Earnings from Continuing Operations | -24.87 | -22.03 | -22.83 | -21.65 | -20.63 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.87M | -22.03M | -22.83M | -21.65M | -20.63M |
| EBIT | -26.46M | -24.49M | -22.22M | -20.75M | -20.40M |
| EBITDA | -26.46M | -24.48M | -22.21M | -20.74M | -20.38M |
| EPS Basic | -1.73 | -1.70 | -1.98 | -2.06 | -2.16 |
| Normalized Basic EPS | -1.07 | -1.06 | -1.04 | -1.09 | -1.16 |
| EPS Diluted | -1.73 | -1.70 | -1.98 | -2.06 | -2.16 |
| Normalized Diluted EPS | -1.07 | -1.06 | -1.04 | -1.09 | -1.16 |
| Average Basic Shares Outstanding | 57.50M | 52.07M | 47.55M | 42.68M | 38.26M |
| Average Diluted Shares Outstanding | 57.50M | 52.07M | 47.55M | 42.68M | 38.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |